Highlands Oncology Group, PA

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Melanoma3 trials
• Childhood cancers2 trials
• Colorectal cancer2 trials
• Head and neck cancer2 trials
• Metastatic breast cancer2 trials
• Thyroid cancer2 trials
• Bladder cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 35 trials
• Phase 13 trials
• Phase 1/22 trials
• Phase 22 trials

Status

• Recruiting6 trials
• Active, not recruiting5 trials
• Completed1 trial

Lead sponsor

• Pfizer10 trials
• Seagen, a wholly owned subsidiary of Pfizer1 trial
• University of Arkansas1 trial

Running trials

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

  NCT06447662· Phase 1· Pfizer· Source

• Recruiting

  Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

  NCT05952934· Phase 2· University of Arkansas· Source

  Contact: Jennifer Worth

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

  NCT05538130· Phase 1· Pfizer· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

  NCT05355701· Phase 1· Pfizer· Source

• Active, not recruiting

  Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

  NCT05059522· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Bladder cancer1 recruiting
• Head and neck cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

  NCT04609566· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source